help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vugmeyster, Y.
Right arrow Articles by Danilenko, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vugmeyster, Y.
Right arrow Articles by Danilenko, D. M.
(American Journal of Pathology. 2006;168:476-489.)
© 2006 American Society for Investigative Pathology

A Soluble BAFF Antagonist, BR3-Fc, Decreases Peripheral Blood B Cells and Lymphoid Tissue Marginal Zone and Follicular B Cells in Cynomolgus Monkeys

Yulia Vugmeyster*, Dhaya Seshasayee*, Wesley Chang*, Anahid Storn*, Kathy Howell*, Susan Sa*, Tenea Nelson*, Flavius Martin*, Iqbal Grewal*, Ellen Gilkerson*, Ben Wu*, Jeff Thompson{dagger}, Barbara N. Ehrenfels{dagger}, Song Ren*, An Song*, Thomas R. Gelzleichter* and Dimitry M. Danilenko*

From Genentech, Inc.,* South San Francisco, California; and Biogen Idec, Inc.,{dagger} Cambridge, Massachusetts

BAFF (also known as BLyS), a member of the tumor necrosis factor superfamily, plays a critical role in the maturation and development of B cells. BAFF has three receptors on B cells, the most crucial of which is BR3. In this study, we demonstrate the biological outcome of BAFF blockade in cynomolgus monkeys using a soluble fusion protein consisting of human BR3 and human IgG1 Fc. In vitro, BR3-Fc blocked BAFF-mediated survival and proliferation of cynomolgus monkey B cells. Weekly treatment of cynomolgus monkeys with BR3-Fc for 13 to 18 weeks resulted in significant B-cell reduction in the peripheral blood and in lymphoid organs. CD21high B cells in lymphoid tissues, a subset analogous to human marginal zone B cells, expressed nearly twofold higher BR3 levels than did CD21med B cells. Lymphoid tissue flow cytometric analysis showed that BR3-Fc reduced this CD21high B-cell subset to a greater extent than it reduced CD21med B cells. Dual-label immunohistochemistry and morphometric image analysis supported these results by demonstrating that BR3-Fc reduced a significant proportion of the B cells within the splenic inner and outer marginal zones. These findings should prove very useful in guiding the desired therapeutic use of BR3-Fc for autoimmune diseases in the clinic.




This article has been cited by other articles:


Home page
 BloodHome page
W. Y. Lin, Q. Gong, D. Seshasayee, Z. Lin, Q. Ou, S. Ye, E. Suto, J. Shu, W. Pun Lee, C.-W. V. Lee, et al.
Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade
Blood, December 1, 2007; 110(12): 3959 - 3967.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. V. Lee, S. G. Hymowitz, H. J. Wallweber, N. C. Gordon, K. L. Billeci, S.-P. Tsai, D. M. Compaan, J. Yin, Q. Gong, R. F. Kelley, et al.
Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells
Blood, November 1, 2006; 108(9): 3103 - 3111.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Society for Investigative Pathology.